Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients

Conflict of interest

Masahiro Takada received institutional grants from AstraZeneca (Osaka, Japan), Daiichi Sankyo (Tokyo, Japan), Eisai (Tokyo, Japan), Yakult (Tokyo, Japan), Medbis (Kyoto, Japan), Taiho (Tokyo, Japan), the Japan Breast Cancer Research Group Association (JBCRG), the Kyoto Breast Cancer Research Network (KBCRN), ABCSG, and IQVIA Japan; and personal fees from Chugai (Tokyo, Japan), AstraZeneca, Daiichi Sankyo, Taiho, Pfizer (Tokyo, Japan), Eli Lilly (Kobe, Japan), Eisai, and MSD (Tokyo, Japan).Nobuko Kawaguchi-Sakita: Dr. Kawaguchi-Sakita reports personal fees from Chugai, personal fees from Daiichi-Sankyo, grants from Fuji Chemical Industrial, personal fees from Fujitsu, personal fees from Kyowa Kirin, personal fees from Meiji Seika Pharma, personal fees from Nippon Kayaku, personal fees from Pfizer, personal fees from Yakult, personal fees from NTT, personal fees from PRiME-R, personal fees from CANNON Medical, personal fees from HUG, personal fees from NTT-DATA, personal fees from IHC, grants from Kansai Medical Net, personal fees from Taiho, personal fees from Eisai, personal fees from Astra Zeneca, personal fees from Zene, outside the submitted work. Masakazu Toi: Dr. Toi has funding from Chugai, Takeda, Pfizer, Taiho, JBCRG assoc., KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science and Sanwa Shurui as a research grant. He has funding from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan and Sysmex as compensation for Lecture honoraria or lecture chairs. He has funding from Daiichi-Sankyo, Eli Lilly and companies, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net for Advisory board. He has funding from British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, and Asian Journal of Breast Surgery for Associate editor.

留言 (0)

沒有登入
gif